KRAS and non-small cell lung carcinoma: However, it's worth noting that in the context of treating non-small cell lung cancers (NSCLCs) with KRAS inhibitors like ARS1620, a significant challenge arose as these tumors frequently developed resistance during the course of treatment [28], [60], [62].